Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

Many patients with BRAF inhibitor resistance can develop disease at new sites, suggesting that drug-induced selection pressure drives metastasis. Here we used mass spectrometry-based phosphoproteomic screening to uncover ligand-independent EphA2 signaling as an adaptation to BRAF inhibitor therapy t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Discov
Autors principals: Paraiso, Kim H. T., Thakur, Meghna Das, Fang, Bin, Koomen, John M., Fedorenko, Inna V., John, Jobin K., Tsao, Hensin, Flaherty, Keith T., Sondak, Vernon K., Messina, Jane L., Pasquale, Elena B., Villagra, Alejandro, Rao, Uma N., Kirkwood, John M., Meier, Friedegund, Sloot, Sarah, Gibney, Geoffrey T., Stuart, Darrin, Tawbi, Hussein, Smalley, Keiran S.M.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355213/
https://ncbi.nlm.nih.gov/pubmed/25542447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0293
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars